The Clinical Core operates as the unit of the Oregon Alzheimer's Disease Center (OADC) with responsibility for identification, recruitment, characterization, and follow-up of populations of well-characterized subjects for clinical research. In keeping with the OADC focus, the Clinical Core is organized to optimize research, leading to better defining normal aging and the transitions to mild cognitive impairment (MCI) and early dementia. In order to fulfill this mission, the Clinical Core completes systematic assessments resulting in standardized diagnoses of the research cohorts, which are then entered into the relational database of the OADC. Many types of data are collected in order to be responsive to current and anticipated needs of the research community: clinical histories, neurological examinations, MRI brain images, neuropsychological and behavioral assessments, and laboratory data. The Clinical Core works closely with the other cores of the Center to ensure tissue donations (Neuropathology Core), characterization of biomarkers and genetic associations (Biomarkers and Genetics Core) and smooth transfer, entry, storage and retrieval for analysis of the data (Data Management and Statistics Core). The Clinical Core faculty acts as an important knowledge resource, participating in Education and Information Core educational activities and programs. The Clinical Core is dedicated to on-going evaluation of its identified cohorts and to ensuring that subjects are not lost to follow-up. Several groups form a particular focus of the Clinical Core: 1) early Alzheimer's disease and related dementias;2) non-cognitively impaired or MCI elderly at high risk for developing dementia, emphasizing the oldest old;and 3) subjects reflecting social and racial diversity (African American and isolated rural populations) through the Satellite program. These subject groups and the research resources they create are used for a wide range of studies, including the natural history of aging without cognitive impairment, detection of cognitive decline with unobtrusive in-home monitoring technologies, the genetics of incipient dementia, biomarkers of underlying disease, and novel treatment or prevention regimens for cognitive decline. Implicit in this core is a fundamental commitment to research collaboration both within our local pool of talented investigators, as well as with our colleagues among the larger community of scientists at other ADC's and other relevant research institutions.

Public Health Relevance

The OADC Clinical Core provides the key research faculty, staff, and subject volunteers for the complete characterization of subjects involved in research focused on advancing the clinical science of detection, diagnosis and treatment of early cognitive decline. This ready clinical resource and infrastructure are intended to facilitate research in a manner that is widely shared, collaborative and responsive to the rapid development of knowledge about early dementia or the years before symptoms fully develop.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
2P30AG008017-21
Application #
8013418
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J1))
Project Start
Project End
Budget Start
2010-05-15
Budget End
2011-03-31
Support Year
21
Fiscal Year
2010
Total Cost
$115,405
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Lusardi, Theresa A; Wiedrick, Jack T; Malone, Molly et al. (2018) Analytics of Cerebrospinal Fluid MicroRNA Quantitative PCR Studies. Mol Neurobiol :
Leach, Julia M; Mancini, Martina; Kaye, Jeffrey A et al. (2018) Day-to-Day Variability of Postural Sway and Its Association With Cognitive Function in Older Adults: A Pilot Study. Front Aging Neurosci 10:126
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Mogg, Adrian J; Eessalu, Thomas; Johnson, Megan et al. (2018) In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography. J Pharmacol Exp Ther 365:602-613
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Tulloch, Jessica; Leong, Lesley; Chen, Sunny et al. (2018) APOE DNA methylation is altered in Lewy body dementia. Alzheimers Dement 14:889-894
Wang, Lucy Y; Raskind, Murray A; Wilkinson, Charles W et al. (2018) Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia. Int J Geriatr Psychiatry 33:763-768
Kaur, Antarpreet; Edland, Steven D; Peavy, Guerry M (2018) The MoCA-Memory Index Score: An Efficient Alternative to Paragraph Recall for the Detection of Amnestic Mild Cognitive Impairment. Alzheimer Dis Assoc Disord 32:120-124
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71

Showing the most recent 10 out of 482 publications